UKEi001-A-2

Biallelic NRAP-KO

The cell line is not validated yet.

General

Cell Line

hPSCreg name UKEi001-A-2
Cite as:
UKEi001-A-2
Alternative name(s)
Biallelic NRAP-KO
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines No similar lines found.
Last update 4th November 2025
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator University Medical Center Hamburg-Eppendorf (UKE)
Owner University Medical Center Hamburg-Eppendorf (UKE)
Distributors
Derivation country Germany

General Information

Publications
* Is the cell line readily obtainable for third parties?
Yes
Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
Subclone of

Donor Information

General Donor Information

Sex female

Phenotype and Disease related information (Donor)

Diseases No disease was diagnosed.
Family history None
Is the medical history available upon request? On request
Is clinical information available? On request. Healthy heart (MRI, echocardiography).

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
Yes
Illumina TruSight Cardio Sequencing Kit.
No pathogenic or likely pathogenic variants detected

Donor Relations

Other cell lines of this donor

External Databases (Donor)

BioSamples SAMEA6235103

Ethics

Also have a look at the ethics information for the parental line UKEi001-A .
Is there an MTA available for the cell line? No
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? IDT
Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? No

hIPSC Derivation

General

The source cell information can be found in the parental cell line UKEi001-A.
Passage number reprogrammed 29

Reprogramming method

Vector type Non-integrating
Vector Sendai virus
Is reprogramming vector detectable?
No
Methods used
RT-PCR

Vector free reprogramming

Other

Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions

Surface coating Matrigel/Geltrex
Passage method Enzymatically
Accutase
O2 Concentration 5 %
CO2 Concentration 5 %
Medium Other medium:
Base medium: DMEM/F12:FTDA
Main protein source: Albumine
Serum concentration: 0 %
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Yes

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
SSEA-3
Yes
NANOG
Yes
Differentiation Potency
SOX17
In vitro directed differentiation
Marker Expressed
SOX17
Yes
FOXA2
Yes
Cardiac Muscle Cell
Ont Id: CL_0000746
In vitro directed differentiation
Ectoderm
Ont Id: UBERON_0000924
In vitro directed differentiation
Marker Expressed
NCAM1
Yes
PAX6
Yes

Microbiology / Virus Screening

HIV 1 Negative
HIV 2 Negative
Hepatitis B Negative
Hepatitis C Negative
Mycoplasma Negative

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46,XX
Passage number: p32
Karyotyping method: G-Banding

Other Genotyping (Cell Line)

Genetic Modification

Disease/phenotype related modifications
Synonyms
  • Cardiomyopathy
  • CARDIOMYOPATHY
  • Cardiomyopathy, NOS
Genetic modifications
Gene knock-out
10q25.3
Deletion of 5328 bp on one NRAP allele and a 16 bp deletion on the other NRAP allele for the biallelic knockout (NRAP-KO)
CRISPR-associated (CRISPR/Cas) System